200 related articles for article (PubMed ID: 11468200)
1. Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes: prospective analysis from PURSUIT.
Tardiff BE; Jennings LK; Harrington RA; Gretler D; Potthoff RF; Vorchheimer DA; Eisenberg PR; Lincoff AM; Labinaz M; Joseph DM; McDougal MF; Kleiman NS;
Circulation; 2001 Jul; 104(4):399-405. PubMed ID: 11468200
[TBL] [Abstract][Full Text] [Related]
2. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA
Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950
[TBL] [Abstract][Full Text] [Related]
3. Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors.
Proimos G
J Thromb Thrombolysis; 2001 Apr; 11(2):99-110. PubMed ID: 11406724
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study).
Tcheng JE; Talley JD; O'Shea JC; Gilchrist IC; Kleiman NS; Grines CL; Davidson CJ; Lincoff AM; Califf RM; Jennings LK; Kitt MM; Lorenz TJ
Am J Cardiol; 2001 Nov; 88(10):1097-102. PubMed ID: 11703951
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention.
Gilchrist IC; O'Shea JC; Kosoglou T; Jennings LK; Lorenz TJ; Kitt MM; Kleiman NS; Talley D; Aguirre F; Davidson C; Runyon J; Tcheng JE
Circulation; 2001 Jul; 104(4):406-11. PubMed ID: 11468201
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic use of intravenous eptifibatide in patients undergoing percutaneous coronary intervention: acute coronary syndromes and elective stenting.
Granada JF; Kleiman NS
Am J Cardiovasc Drugs; 2004; 4(1):31-41. PubMed ID: 14967064
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacology of eptifibatide.
Phillips DR; Scarborough RM
Am J Cardiol; 1997 Aug; 80(4A):11B-20B. PubMed ID: 9291241
[TBL] [Abstract][Full Text] [Related]
8. Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
Lauer MA; Houghtaling PL; Peterson JG; Granger CB; Bhatt DL; Sapp SK; Simoons ML; Harrington RA; Topol EJ; Lincoff AM;
Circulation; 2001 Dec; 104(23):2772-7. PubMed ID: 11733393
[TBL] [Abstract][Full Text] [Related]
9. Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: effect of inhibition of platelet glycoprotein IIb/IIIa with eptifibatide. The PURSUIT trial investigators.
Hasdai D; Holmes DR; Criger DA; Topol EJ; Califf RM; Wilcox RG; Paolasso E; Simoons M; Deckers J; Harrington RA
Am Heart J; 2000 Mar; 139(3):454-60. PubMed ID: 10689260
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing.
Hobbach HP; Schuster P
Z Kardiol; 2003 Mar; 92(3):213-8. PubMed ID: 12658467
[TBL] [Abstract][Full Text] [Related]
11. Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
Lincoff AM; Harrington RA; Califf RM; Hochman JS; Guerci AD; Ohman EM; Pepine CJ; Kopecky SL; Kleiman NS; Pacchiana CM; Berdan LG; Kitt MM; Simoons ML; Topol EJ
Circulation; 2000 Sep; 102(10):1093-100. PubMed ID: 10973836
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide.
Kleiman NS; Klem J; Fernandes LS; Rubin H; Challa S; Solomon S; Maresh K; Arora U; Klem E; Buergler J; Mathew S; Browning A; DeLao T
Am Heart J; 2002 Apr; 143(4):585-93. PubMed ID: 11923794
[TBL] [Abstract][Full Text] [Related]
13. Ticagrelor and Eptifibatide Bolus Versus Ticagrelor and Eptifibatide Bolus With 2-Hour Infusion in High-Risk Acute Coronary Syndromes Patients Undergoing Early Percutaneous Coronary Intervention.
Marian MJ; Alli O; Al Solaiman F; Brott BC; Sasse M; Leesar T; Prabhu SD; Leesar MA
J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28611098
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
Labinaz M; Kilaru R; Pieper K; Marso SP; Kitt MM; Simoons ML; Califf RM; Topol EJ; Armstrong PW; Harrington RA
Circulation; 2002 Jan; 105(3):322-7. PubMed ID: 11804987
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of citrate versus PPACK anticoagulation on measured platelet inhibition by abciximab, eptifibatide and tirofiban.
Kereiakes DJ; Lorenz T; Young JJ; Kukielka G; Mueller MN; Nanniazzi-Alaimo L; Phillips DR
J Thromb Thrombolysis; 2001 Oct; 12(2):123-7. PubMed ID: 11729363
[TBL] [Abstract][Full Text] [Related]
16. Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators.
Mahaffey KW; Harrington RA; Simoons ML; Granger CB; Graffagnino C; Alberts MJ; Laskowitz DT; Miller JM; Sloan MA; Berdan LG; MacAulay CM; Lincoff AM; Deckers J; Topol EJ; Califf RM
Circulation; 1999 May; 99(18):2371-7. PubMed ID: 10318656
[TBL] [Abstract][Full Text] [Related]
17. Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy.
Harrington RA
Am J Cardiol; 1997 Aug; 80(4A):34B-38B. PubMed ID: 9291244
[TBL] [Abstract][Full Text] [Related]
18. Eptifibatide: a pharmacoeconomic review of its use in percutaneous coronary intervention and acute coronary syndromes.
Plosker GL; Ibbotson T
Pharmacoeconomics; 2003; 21(12):885-912. PubMed ID: 12908844
[TBL] [Abstract][Full Text] [Related]
19. Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrelin Therapy.
Dyke CM; Bhatia D; Lorenz TJ; Marso SP; Tardiff BE; Hogeboom C; Harrington RA
Ann Thorac Surg; 2000 Sep; 70(3):866-71; discussion 871-2. PubMed ID: 11016325
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes.
Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators
N Engl J Med; 1998 Aug; 339(7):436-43. PubMed ID: 9705684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
